Thunder Bay Regional Research Institute (TBRRI)

Johnson & Johnson Innovation Opens JLABS @ Toronto

TORONTO (May 11, 2016) –  Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ... Read more

MaRS Innovation featured in International Innovation magazine

MaRS Innovation and its member institutions are is profiled in International Innovation's July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI's president and CEO, written by Rosemary Peters. The article is posted on the publication's website and viewable through a digital interface (pages 80 and 81). Here's an excerpt from Dr. Hofstein's comments: "Canada's academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the ... Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ... Read more

XLV Diagnostics Inc. secures $3 million Series A from Boston-based investor

THUNDER BAY, ON (May 28,2014) – XLV Diagnostics Inc., a MaRS Innovation (MI) start-up company based in Thunder Bay and specializing in low-cost, next-generation digital mammography machines, has closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust. The funding will support continued product development and regulatory approval. XLV’s product will provide mammography image quality equivalent to top-of-the-line mammography machines currently in use, and will do so at a fraction of the cost of current generation ... Read more

MI’s Rafi Hofstein featured in Biotechnology Focus

In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein's recent visit to learn more of the emerging science and technology markets in Singapore and Japan. The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore's proximity to medical technology markets in India and China. Hofstein joined other delegates from Canada, including Dr. Mark Poznansky, president and CEO of the ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor. Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money. XLV’s solution has ... Read more

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed? MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ... Read more

MaRS Innovation welcomes Thunder Bay Regional Research Institute as newest member

Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes Thunder Bay Regional Research Institute (TBRRI) as its newest member. MaRS Innovation is an incorporated non-profit organization with an international, independent, industry-led Board of Directors. It is the commercialization agent for 16 member institutions that are leading Ontario life sciences and commercialization agents. Partners include the University of Toronto, Sunnybrook Health Sciences Centre, ... Read more